Related MeSH Hierarchy (10)
Diseases [C] » Urogenital Diseases [C12] » Female Urogenital Diseases and Pregnancy Complications » Female Urogenital Diseases » Urogenital Abnormalities » Disorders of Sex Development » 46, XX Disorders of Sex Development » Hyperandrogenism
Diseases [C] » Urogenital Diseases [C12] » Female Urogenital Diseases and Pregnancy Complications » Female Urogenital Diseases » Urogenital Abnormalities » Disorders of Sex Development » Adrenogenital Syndrome » Hyperandrogenism
Diseases [C] » Urogenital Diseases [C12] » Male Urogenital Diseases » Urogenital Abnormalities » Disorders of Sex Development » 46, XX Disorders of Sex Development » Hyperandrogenism
Diseases [C] » Urogenital Diseases [C12] » Male Urogenital Diseases » Urogenital Abnormalities » Disorders of Sex Development » Adrenogenital Syndrome » Hyperandrogenism
Diseases [C] » Urogenital Diseases [C12] » Urogenital Abnormalities » Disorders of Sex Development » 46, XX Disorders of Sex Development » Hyperandrogenism
Diseases [C] » Urogenital Diseases [C12] » Urogenital Abnormalities » Disorders of Sex Development » Adrenogenital Syndrome » Hyperandrogenism
Diseases [C] » Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] » Congenital Abnormalities » Urogenital Abnormalities » Disorders of Sex Development » 46, XX Disorders of Sex Development » Hyperandrogenism
Diseases [C] » Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] » Congenital Abnormalities » Urogenital Abnormalities » Disorders of Sex Development » Adrenogenital Syndrome » Hyperandrogenism
Diseases [C] » Endocrine System Diseases [C19] » Gonadal Disorders » Disorders of Sex Development » 46, XX Disorders of Sex Development » Hyperandrogenism
Diseases [C] » Endocrine System Diseases [C19] » Gonadal Disorders » Disorders of Sex Development » Adrenogenital Syndrome » Hyperandrogenism
Description
A condition caused by the excessive secretion of ANDROGENS from the ADRENAL CORTEX; the OVARIES; or the TESTES. The clinical significance in males is negligible. In women, the common manifestations are HIRSUTISM and VIRILISM as seen in patients with POLYCYSTIC OVARY SYNDROME and ADRENOCORTICAL HYPERFUNCTION. MeSH
Hierarchy View
Phase 4 Indicated Drugs (7)
Phase 3 Indicated Drugs (2)
Phase 2 Indicated Drugs (4)
Phase 1 Indicated Drugs (1)
Other Experimental Indicated Drugs (9)
Organization Involved with Phase 4 Indications (8)
Organization Involved with Phase 3 Indications (3)
Organization Involved with Phase 2 Indications (15)
Organization Involved with Phase 1 Indications (3)
Organization Involved with Other Experimental Indications (8)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
